Dabigatran etexilate-d<sub>13</sub>

Dabigatran etexilate-d13

CAT N°: 18451
Price:

From 92.00 78.20

Dabigatran etexilate-d13 is intended for use as an internal standard for the quantification of dabigatran etexilate (Item Nos. 17131 | 35248) by GC- or LC-MS. Dabigatran etexilate is a prodrug form of the thrombin inhibitor dabigatran (Item No. 17133).{62763} It inhibits thrombin-induced platelet aggregation in isolated rabbit platelets (IC50 = 0.337 µM) and inhibits thrombus formation in a rat model of venous thrombosis (ED50 = 7.8 µmol/kg). Formulations containing dabigatran etexilate have been used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[[2-[[[4-[[[(hexyl-d13-oxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-?-alanine, ethyl ester
  • Correlated keywords
    • deuterated deuterium anti-thrombotic CYP450 BIBR 1048 BIBR1048 Prazaxa
  • Product Overview:
    Dabigatran etexilate-d13 is intended for use as an internal standard for the quantification of dabigatran etexilate (Item Nos. 17131 | 35248) by GC- or LC-MS. Dabigatran etexilate is a prodrug form of the thrombin inhibitor dabigatran (Item No. 17133).{62763} It inhibits thrombin-induced platelet aggregation in isolated rabbit platelets (IC50 = 0.337 µM) and inhibits thrombus formation in a rat model of venous thrombosis (ED50 = 7.8 µmol/kg). Formulations containing dabigatran etexilate have been used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism.

We also advise you